Article

Mutations based on viral decay acceleration in the HIV-1 genomes of a clinical population treated with the mutagenic nucleoside KP1461

2011-01-01

Abstract excerpt

No abstract is available from the source.

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 9e767442-b466-5db4-9b96-8edb4775abae
DOI: 10.1186/1742-4690-8-s2-p84
PMCID: PMC3236977

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Mutations based on viral decay acceleration in the HIV-1 genomes of a clinical population treated with the mutagenic nucleoside KP1461DOI 10.1186/1742-4690-8-s2-p84Read

Mutation of HIV-1 genomes in a clinical population treated with the mutagenic nucleoside KP1461.Semantic proximity Read

The evolutionary safety of mutagenic drugs should be assessed before drug approval.Semantic proximity Read

Safety, tolerability, and efficacy of KP-1461 as monotherapy for 124 days in antiretroviral-experienced, HIV type 1-infected subjects.Semantic proximity Read

Evolutionary safety of death by mutagenesisSemantic proximity Read

Perspective - Lethal Mutagenesis of HIV by Mutagenic Ribonucleoside AnalogsSemantic proximity Read

Back to the future: revisiting HIV-1 lethal mutagenesis.Semantic proximity Read

Evolutionary safety of death by mutagenesisSemantic proximity Read

KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis.Semantic proximity Read

High-throughput profiling of point mutations across the HIV-1 genomeSemantic proximity Read

5,6-Dihydro-5-aza-2'-deoxycytidine potentiates the anti-HIV-1 activity of ribonucleotide reductase inhibitors.Semantic proximity Read

Deep sequencing analysis of mutations resulting from the incorporation of dNTP analogs.Semantic proximity Read

Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: the special case of molnupiravirSemantic proximity Read